Subject: Agreements between the University of Michigan and Sarcoma Alliance for Research through Collaboration

Action Requested: Authorization to enter into Agreements

Preamble:

A statutory conflict of interest situation was identified by DRDA while reviewing the Proposal Approval Form that then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was developed and approved by this Board and agreed to by the parties involved in this plan.

These proposed agreements (Agreements) fall under the State of Michigan Conflict of Interest Statute because Dr. Laurence Baker is both an employee of the University and the Co-Founder, Executive Director, President and Director of the Sarcoma Alliance for Research through Collaboration (SARC). The law permits the University to enter into such Agreements provided it is disclosed to the executive officers and approved in advance by a 2/3 vote of the Regents.

Background:

Dr. Laurence Baker, Professor of Internal Medicine, Division of Hematology/Oncology and Deputy Director, Comprehensive Cancer Center, is the Co-Founder, Executive Director, President and Director of SARC, a non-profit research corporation located in Ann Arbor. SARC will be funded primarily by contracts and gifts. Dr. Baker receives no compensation from SARC and has no financial interest in SARC. The University’s conduct of the two SARC sponsored clinical trials will be under the direction of Dr. Scott Schuetze, Clinical Assistant Professor of Internal Medicine, Division of Hematology/Oncology, who has no proprietary or other interest in SARC. Dr. Baker will serve as a co-investigator for each of these trials.

Nature of the Agreements:

SARC has received contracts from Aventis and Lilly to provide drugs to support clinical trials that will be funded by SARC and conducted at major cancer centers, including the University.

Terms of the Agreements:

The terms of the Agreements are acceptable and conform to University policy. The amounts of the two Agreements to the University are $17,500 and $52,500,
respectively. The periods of performance are both twelve months. Human subject approval will be obtained prior to commencement of the clinical trials.

**Impact of the Agreements:**

The Agreements will enable the University to participate in important clinical research efforts to determine more effective treatment for patients with recurrent Ewing's sarcoma, recurrent osteosarcoma, unresectable or locally recurrent chondrosarcoma and unresectable soft tissue sarcoma.

**Recommendation:**

The Medical School Conflict of Interest Board approved these two SARC sponsored clinical trials and a plan has been developed to manage potential conflicts. In light of this disclosure and our finding that the Agreements conform to standard University practices, I recommend that the Board of Regents approve of the University entering into the Agreements with the Sarcoma Alliance for Research through Collaboration.

Respectfully submitted,

[Signature]

Pawwaz I. Ulaby
Vice President for Research

April 2005